Treatment of invasive candidiasis: What guidelines recommend

• Autores: Cristóbal Gallego Muñoz, Francisco Javier Ferreira Alfaya
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 19, Nº. 4, 2017, págs. 270-273
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Candidemia and invasive candidiasis are major causes of morbidity and mortality, and their incidence is increasing because of the growing complexity of patient. Retrospective analyses have shown that early antifungal treatments can improve outcomes. In this update, we review and summarize the main evidence about treatment of invasive candidiasis according to recommendations of principal guidelines. Method: An exhaustive search of the published guidelines in referential data sources was performed, up to October 20, 2016. Results: We included the guidelines of Infectious Diseases Society of America (IDSA) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID). Conclusions: Although the recommendations are clear in general, it is difficult to draw any conclusions concerning the choice of antifungal agent and duration of treatment for the less common forms of invasive candidiasis because of the lack of good-quality studies